Thursday, 5 November 2026European Markets

ALPES (COMPAGNIE) And KID Have A High Dividend Yield And Return On Equity In The Consumer Cyclical Sector.

Loading stream...

(vianews) - alpes (compagnie) (cda.pa) is among this list of stock assets with the highest dividend rate and return on equity on the consumer cyclical sector.

financial asset price forward dividend yield return on equity
alpes (compagnie) (cda.pa) €12.70 6.87% 10.59%
kid (kid.ol) kr131.20 6.85% 26.8%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. alpes (compagnie) (cda.pa)

6.87% forward dividend yield and 10.59% return on equity

compagnie des alpes sa, together with its subsidiaries, engages in the operation of leisure facilities in france. the company operates through ski areas and leisure parks segments. the ski areas segment operates ski lifts; and maintains slopes. this segment also operates ski resorts. the leisure parks segment is involved in the operation of amusement parks, combined amusement and animal parks, water parks, waxwork museums, and tourist sites. compagnie des alpes sa was founded in 1989 and is headquartered in paris, france.

earnings per share

as for profitability, alpes (compagnie) has a trailing twelve months eps of €2.17.

pe ratio

alpes (compagnie) has a trailing twelve months price to earnings ratio of 5.85. meaning, the purchaser of the share is investing €5.85 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.59%.

volatility

alpes (compagnie)'s last week, last month's, and last quarter's current intraday variation average was a negative 0.66%, a negative 0.55%, and a positive 1.45%.

alpes (compagnie)'s highest amplitude of average volatility was 1.20% (last week), 1.28% (last month), and 1.45% (last quarter).

revenue growth

year-on-year quarterly revenue growth grew by 12.2%, now sitting on 1.21b for the twelve trailing months.

more news about alpes (compagnie).

2. kid (kid.ol)

6.85% forward dividend yield and 26.8% return on equity

kid asa, together with its subsidiaries, operates as a home textile retailer in norway, sweden, finland, and estonia. it designs, sources, markets, and sells a range of home and interior products, including textiles, curtains, bed linens, home accessories, decorations, furniture, and other interior products through retail stores and online platforms. the company provides its products under the kid, hemtex, dekosol, nordun, and premium collection brands. it also offers logistics services. the company was formerly known as nordisk tekstil holding as and changed its name to kid asa. kid asa was founded in 1937 and is headquartered in lier, norway.

earnings per share

as for profitability, kid has a trailing twelve months eps of kr8.65.

pe ratio

kid has a trailing twelve months price to earnings ratio of 15.17. meaning, the purchaser of the share is investing kr15.17 for every norwegian krone of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 26.8%.

sales growth

kid's sales growth is 10.2% for the ongoing quarter and 7.5% for the next.

moving average

kid's worth is below its 50-day moving average of kr142.34 and above its 200-day moving average of kr130.14.

more news about kid.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com